Skip to main content

Medicenna Therapeutics Corp(MDNA-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.59
Day High0.62
Open:0.62
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
GlobeNewswire
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
GlobeNewswire
Medicenna Therapeutics Announces Participation in Upcoming Conferences
GlobeNewswire
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
GlobeNewswire
Medicenna Announces Changes to Board Composition
GlobeNewswire
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
GlobeNewswire
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
GlobeNewswire
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
GlobeNewswire
Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
GlobeNewswire
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
GlobeNewswire
Medicenna Therapeutics Announces Participation in Upcoming Conferences
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Announces Results of Annual Meeting of Shareholders
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
Baystreet
Stocks in play: Medicenna Therapeutics Corp
GlobeNewswire
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
AI-generated - The Globe and Mail
Medicenna Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (MDNA)
AI-generated - The Globe and Mail
Medicenna Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (MDNA)
GlobeNewswire
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
AI-generated - The Globe and Mail
Medicenna Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (MDNA)
Baystreet
Stocks in play: Medicenna Therapeutics Corp.

Profile

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.